Share ownership Ocugen, Inc.

OCGN

US67577C1053

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 02:30:00 17/01/2026 am IST			5-day change	1st Jan Change
1.690 ^USD	+4.32%		+12.67%	+25.19%

15/01	Ocugen, Inc. - Special Call
15/01	Ocugen Says Gene Therapy Reduced Lesion Growth by 46% in Eye Disease Trial	MT

Share class: Ocugen, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	29,14,41,780	28,72,22,645 ( 98.55 %)	1,21,500 ( 0.0417 %)	98.55 %

Major shareholders: Ocugen, Inc.

Name	Equities	%	Valuation
Janus Henderson Investors US LLC 6.404 %	2,00,00,000	6.404 %	27 M $
Vanguard Fiduciary Trust Co. 4.874 %	1,52,23,585	4.874 %	21 M $
Shankar Musunuri 1.954 %	61,01,223	1.954 %	8 M $
Millennium Management LLC 1.333 %	41,62,149	1.333 %	6 M $
GMT Capital Corp. 1.33 %	41,53,798	1.33 %	6 M $
BlackRock Institutional Trust Co. NA 1.242 %	38,78,705	1.242 %	5 M $
Geode Capital Management LLC 1.177 %	36,77,192	1.177 %	5 M $
Citadel Securities GP LLC 0.5021 %	15,68,211	0.5021 %	2 M $
STATE STREET CORPORATION 0.434 %	13,55,377	0.434 %	2 M $
Junge Zhang 0.3731 %	11,65,182	0.3731 %	2 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	19.66%
Individuals	2.72%
Other	1.35%
State Street Corp.	0.43%
Baader Bank AG	0.01%
Unknown	75.83%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	20.56%
Individuals	2.72%
United Kingdom	0.53%
Cayman Islands	0.15%
Canada	0.11%
Ireland	0.06%
Singapore	0.04%
Germany	0.01%
Japan	0.01%

Based on 1000 largest holdings

Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.

Employees

Sector

Biotechnology & Medical Research

Calendar

27/03 - Q4 2025 Earnings Release (Projected)

More about the company